Munich - Delayed Quote EUR

Diamyd Medical AB (DMN.MU)

0.8290
+0.0180
+(2.22%)
As of 8:03:44 AM GMT+2. Market Open.
Currency in SEK All numbers in thousands
Download
Breakdown
TTM
8/31/2024
8/31/2023
8/31/2022
8/31/2021
Total Revenue
182
130
546
454
253
Cost of Revenue
3,938
3,710
3,634
4,403
2,501
Gross Profit
-3,756
-3,580
-3,088
-3,949
-2,248
Operating Expense
172,447
143,694
112,758
110,987
83,633
Operating Income
-176,203
-147,274
-115,846
-114,936
-85,881
Net Non Operating Interest Income Expense
4,170
3,745
1,048
8,006
1,512
Pretax Income
-170,847
-151,850
-116,073
-103,516
60,045
Tax Provision
0
0
0
0
0
Net Income Common Stockholders
-170,847
-151,850
-116,073
-103,517
60,046
Diluted NI Available to Com Stockholders
-170,847
-151,850
-116,073
-103,517
60,046
Basic EPS
-1.69
-1.59
-1.49
-1.36
0.87
Diluted EPS
-1.69
-1.59
-1.49
-1.36
0.87
Basic Average Shares
101,141.3520
95,154.0750
78,650.4940
78,749.9500
71,818.4050
Diluted Average Shares
101,141.3520
95,154.0750
78,650.4940
78,749.9500
71,818.4050
Total Operating Income as Reported
-173,200
-146,567
-120,806
-118,176
-85,880
Total Expenses
176,385
147,404
116,392
115,390
86,134
Net Income from Continuing & Discontinued Operation
-170,847
-151,850
-116,073
-103,517
60,046
Normalized Income
-163,503
-137,295
-116,073
-110,170
-84,368
Interest Income
4,969
3,753
1,051
8,259
1,965
Interest Expense
799
8
3
253
453
Net Interest Income
4,170
3,745
1,048
8,006
1,512
EBIT
-170,048
-151,842
-116,070
-103,263
60,498
EBITDA
-158,514
-140,851
-111,201
-98,880
61,280
Reconciled Cost of Revenue
3,938
3,710
3,634
4,403
2,501
Reconciled Depreciation
11,534
10,991
4,869
4,383
782
Net Income from Continuing Operation Net Minority Interest
-170,847
-151,850
-116,073
-103,517
60,046
Total Unusual Items Excluding Goodwill
-7,344
-14,555
0
6,653
144,414
Total Unusual Items
-7,344
-14,555
0
6,653
144,414
Normalized EBITDA
-151,170
-126,296
-111,201
-105,533
-83,134
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
8/31/2021 - 10/15/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

IVBIY Innovent Biologics Inc.
29.00
0.00%
 
KRBPQ Kiromic BioPharma, Inc.
0.0605
0.00%
 
KANT Kineta, Inc.
0.1975
-10.23%
 
RSPI RespireRx Pharmaceuticals Inc.
0.0015
0.00%
 
TSBX Turnstone Biologics Corp.
0.3127
-2.31%
 
CLYM Climb Bio, Inc.
1.1800
0.00%
 
PMN ProMIS Neurosciences, Inc.
0.5000
0.00%
 
IVA Inventiva S.A.
3.3900
-0.07%
 
CHRO Channel Therapeutics Corporation
1.0200
+10.22%
 
AVBP ArriVent BioPharma, Inc.
22.00
+3.53%